Focus Partners Advisor Solutions LLC Grows Holdings in United Therapeutics Corporation $UTHR

Focus Partners Advisor Solutions LLC grew its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 115.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,136 shares of the biotechnology company’s stock after acquiring an additional 2,220 shares during the quarter. Focus Partners Advisor Solutions LLC’s holdings in United Therapeutics were worth $2,015,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of UTHR. Darwin Global Management Ltd. acquired a new position in shares of United Therapeutics during the 3rd quarter valued at about $317,617,000. Norges Bank acquired a new position in shares of United Therapeutics during the 4th quarter valued at about $293,418,000. Baillie Gifford & Co. acquired a new position in shares of United Therapeutics during the 4th quarter valued at about $157,390,000. Balyasny Asset Management L.P. increased its stake in shares of United Therapeutics by 863.9% during the 2nd quarter. Balyasny Asset Management L.P. now owns 152,727 shares of the biotechnology company’s stock valued at $43,886,000 after acquiring an additional 136,883 shares during the last quarter. Finally, Sofinnova Investments Inc. acquired a new position in shares of United Therapeutics during the 2nd quarter valued at about $34,055,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Activity at United Therapeutics

In related news, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction on Monday, March 23rd. The stock was sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at $9,956,712.48. This trade represents a 34.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last three months, insiders sold 625,059 shares of company stock worth $352,648,188. Corporate insiders own 8.60% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Oppenheimer upped their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. Finally, Royal Bank Of Canada dropped their price objective on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $619.42.

United Therapeutics Trading Down 1.6%

United Therapeutics stock opened at $544.10 on Thursday. The stock has a market cap of $23.10 billion, a P/E ratio of 20.08, a price-to-earnings-growth ratio of 1.80 and a beta of 0.57. The stock has a 50 day moving average of $568.19 and a 200-day moving average of $520.67. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). The business had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business’s quarterly revenue was down 1.6% compared to the same quarter last year. During the same quarter last year, the company posted $6.63 earnings per share. As a group, equities analysts predict that United Therapeutics Corporation will post 26.84 earnings per share for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.